Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Arno Therapeutics's Total Liabilities for the quarter that ended in Sep. 2016 was $8.07 Mil. Arno Therapeutics's Total Assets for the quarter that ended in Sep. 2016 was $2.36 Mil.
Therefore, Arno Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2016 was 3.43.
Arno Therapeutics (OTCPK:ARNI) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Arno Therapeutics Liabilities-to-Assets Related Terms
Arno Therapeutics Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Arno Therapeutics's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARNI vs PLPL, BTHE, WIZP: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, Arno Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arno Therapeutics Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arno Therapeutics's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Arno Therapeutics's Liabilities-to-Assets falls into.
Arno Therapeutics Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Arno Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2015 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arno Therapeutics (ARNI) has a Liabilities-to-Assets of 3.43 as of Sep. 2016. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Arno Therapeutics and its competitors.
Is Arno Therapeutics' Liabilities-to-Assets too high?
Arno Therapeutics' current Liabilities-to-Assets is 3.43.
How does Arno Therapeutics' Liabilities-to-Assets compare to PLPL and BTHE?
Arno Therapeutics' Liabilities-to-Assets of 3.43 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Arno Therapeutics and its competitors. Arno Therapeutics's current Liabilities-to-Assets is 3.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arno Therapeutics stock overvalued right now?
Arno Therapeutics (ARNI) has a current Liabilities-to-Assets of 3.43. The current Liabilities-to-Assets is 3.43. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Arno Therapeutics (ARNI), the current Liabilities-to-Assets is 3.43 as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Arno Therapeutics Inc. was a clinical-stage biopharmaceutical company based in the United States that developed drug candidates for cancer and other life-threatening diseases. Its pipeline included Onapristone, an oral progesterone receptor antagonist being studied in endometrial, prostate, and breast cancers; AR-42, a histone deacetylase inhibitor investigated for hematological malignancies and solid tumors; and AR-12, a kinase inhibitor explored for solid tumors, hematological malignancies, and antimicrobial targets. The company relied on a licensing and development model, acquiring or in-licensing compounds and advancing them through preclinical and clinical trials, with the goal of partnering or out-licensing programs to larger pharmaceutical companies. It had no marketed products and generated no product revenue, funding operations primarily through equity financings and collaboration arrangements. Arno Therapeutics was a small, thinly traded public company and later ceased active operations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARNI has been successfully added to your 
